CA3152508A1 - Perk inhibiting pyrrolopyrimidine compounds - Google Patents
Perk inhibiting pyrrolopyrimidine compounds Download PDFInfo
- Publication number
- CA3152508A1 CA3152508A1 CA3152508A CA3152508A CA3152508A1 CA 3152508 A1 CA3152508 A1 CA 3152508A1 CA 3152508 A CA3152508 A CA 3152508A CA 3152508 A CA3152508 A CA 3152508A CA 3152508 A1 CA3152508 A1 CA 3152508A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- pyrrolo
- pyrimidin
- independent
- methy1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893528P | 2019-08-29 | 2019-08-29 | |
| US62/893,528 | 2019-08-29 | ||
| PCT/US2020/048621 WO2021041975A1 (en) | 2019-08-29 | 2020-08-28 | Perk inhibiting pyrrolopyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3152508A1 true CA3152508A1 (en) | 2021-03-04 |
Family
ID=72470610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152508A Pending CA3152508A1 (en) | 2019-08-29 | 2020-08-28 | Perk inhibiting pyrrolopyrimidine compounds |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
| CA3182276A1 (en) | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN117597346A (zh) * | 2021-04-05 | 2024-02-23 | 哈利亚治疗公司 | Nek7抑制剂 |
| JP2024513227A (ja) * | 2021-04-05 | 2024-03-22 | ハリア・セラピューティクス・インコーポレイテッド | Nek7阻害剤 |
| US20240287081A1 (en) * | 2021-06-09 | 2024-08-29 | Icahn School Of Medicine At Mount Sinai | Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof |
| US20250000859A1 (en) | 2021-08-25 | 2025-01-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
| BR9808281A (pt) * | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| US7863444B2 (en) * | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| EP3067356B1 (en) * | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| WO2016085160A2 (ko) * | 2014-11-28 | 2016-06-02 | (주)네오팜 | 발모촉진용 또는 탈모방지용 조성물 |
| GB201508747D0 (en) * | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| WO2017046739A1 (en) * | 2015-09-15 | 2017-03-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazolidinone derivatives as inhibitors of perk |
| TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | 化學化合物 |
| EP3481831B1 (en) * | 2016-07-07 | 2023-09-06 | Daewoong Pharmaceutical Co., Ltd. | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same |
| SI3612519T1 (sl) * | 2017-04-18 | 2022-04-29 | Eli Lilly And Company | Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine |
-
2020
- 2020-08-28 KR KR1020227010197A patent/KR20220066290A/ko not_active Ceased
- 2020-08-28 BR BR112022003584A patent/BR112022003584A2/pt not_active IP Right Cessation
- 2020-08-28 EP EP20771405.6A patent/EP4021908A1/en not_active Withdrawn
- 2020-08-28 MX MX2022002446A patent/MX2022002446A/es unknown
- 2020-08-28 US US17/639,279 patent/US20220356186A1/en active Pending
- 2020-08-28 PH PH1/2022/550491A patent/PH12022550491A1/en unknown
- 2020-08-28 CA CA3152508A patent/CA3152508A1/en active Pending
- 2020-08-28 CN CN202080073530.2A patent/CN114710956A/zh active Pending
- 2020-08-28 AU AU2020336975A patent/AU2020336975A1/en not_active Abandoned
- 2020-08-28 JP JP2022513164A patent/JP2022546414A/ja active Pending
- 2020-08-28 WO PCT/US2020/048621 patent/WO2021041975A1/en not_active Ceased
-
2022
- 2022-02-24 IL IL290889A patent/IL290889A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220066290A (ko) | 2022-05-24 |
| IL290889A (en) | 2022-04-01 |
| BR112022003584A2 (pt) | 2022-05-24 |
| JP2022546414A (ja) | 2022-11-04 |
| WO2021041975A1 (en) | 2021-03-04 |
| AU2020336975A1 (en) | 2022-03-31 |
| PH12022550491A1 (en) | 2023-02-06 |
| CN114710956A (zh) | 2022-07-05 |
| US20220356186A1 (en) | 2022-11-10 |
| EP4021908A1 (en) | 2022-07-06 |
| MX2022002446A (es) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102785137B1 (ko) | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 | |
| KR102824962B1 (ko) | 헤테로시클릭 rip1 억제 화합물 | |
| US20220356186A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| EP3856192B1 (en) | Degraders that target alk and therapeutic uses thereof | |
| CN110267945A (zh) | 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途 | |
| US12331054B2 (en) | Perk inhibiting imidazolopyrazine compounds | |
| WO2021041976A1 (en) | Perk inhibiting indolinyl compounds | |
| US12473296B2 (en) | Perk inhibiting compounds | |
| AU2017335242A1 (en) | Pyridine compound | |
| JP2020509017A (ja) | 新規イソインドリン誘導体、その医薬組成物および使用 | |
| CN111032641A (zh) | 经取代的5-氰基吲哚化合物及其用途 | |
| EP2895166A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
| CN114437116B (zh) | 杂环化合物及其制备方法、药物组合物和应用 | |
| WO2022037631A1 (zh) | 杂环类衍生物及其制备方法和用途 | |
| CN112752758A (zh) | 作为毛细血管扩张性共济失调突变(ATM)激酶的选择性调节剂的1-异丙基-3-甲基-8-(吡啶-3-基)-1,3-二氢-2H-咪唑并[4,5-c]噌啉-2-酮及其用途 | |
| JP2021513549A (ja) | インドール−2、3−ジオキシゲナーゼ阻害剤としてのスピロ化合物 | |
| EP4308564A1 (en) | Polycyclic inhibitors of plasma kallikrein | |
| CN117396469A (zh) | 血浆激肽释放酶的抑制剂 | |
| TW202540096A (zh) | 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| CN114555597B (zh) | 异柠檬酸脱氢酶(idh)抑制剂 | |
| CN106928113B (zh) | 组织蛋白酶k抑制剂及其用途 | |
| WO2023179078A1 (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| TW202227447A (zh) | 嘧啶酮類化合物及其用途 | |
| HK40119524A (en) | Tricyclic compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250825 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260212 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260331 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260413 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |